Brokerages Set Astria Therapeutics, Inc. (NASDAQ:ATXS) Target Price at $25.60

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXS - Get Free Report) have received a consensus recommendation of "Buy" from the six analysts that are covering the stock, Marketbeat reports. Five investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $25.60.

A number of equities analysts have recently issued reports on the company. Wedbush reissued an "outperform" rating and set a $22.00 price target on shares of Astria Therapeutics in a research report on Tuesday, August 13th. TD Cowen initiated coverage on Astria Therapeutics in a report on Monday, July 29th. They set a "buy" rating and a $35.00 target price for the company. Evercore ISI raised Astria Therapeutics to a "strong-buy" rating in a research report on Wednesday, August 14th. Oppenheimer boosted their price target on Astria Therapeutics from $26.00 to $28.00 and gave the stock an "outperform" rating in a research report on Thursday, November 14th. Finally, HC Wainwright reiterated a "buy" rating and issued a $16.00 target price on shares of Astria Therapeutics in a research note on Thursday, November 14th.

Institutional Investors Weigh In On Astria Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ATXS. Quest Partners LLC increased its holdings in shares of Astria Therapeutics by 3,310.6% during the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company's stock valued at $29,000 after acquiring an additional 3,112 shares in the last quarter. PDT Partners LLC acquired a new position in Astria Therapeutics during the 3rd quarter valued at approximately $140,000. SG Americas Securities LLC purchased a new position in shares of Astria Therapeutics in the third quarter worth $155,000. Hsbc Holdings PLC purchased a new position in shares of Astria Therapeutics in the second quarter worth $171,000. Finally, Price T Rowe Associates Inc. MD purchased a new stake in shares of Astria Therapeutics during the first quarter valued at $200,000. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Astria Therapeutics Trading Up 3.3 %

Shares of NASDAQ ATXS traded up $0.31 during mid-day trading on Friday, reaching $9.65. The company had a trading volume of 175,811 shares, compared to its average volume of 239,610. The stock has a market cap of $544.55 million, a price-to-earnings ratio of -4.62 and a beta of 0.71. Astria Therapeutics has a 52 week low of $4.43 and a 52 week high of $16.90. The business's 50-day moving average is $11.25 and its 200-day moving average is $10.62.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.